FDA Expands Allergan's BOTOX Label To Include Eight New Muscles In Patients With Upper Limb Spasticity

by Vandana Singh, Benzinga Editor

July 29, 2021 10:44 AM | 1 min read | Make a Comment

The FDA has approved a label expansion of Allergan's, an AbbVie Inc ABBV company, BOTOX (onabotulinumtoxinA) to include eight new muscles to treat upper limb spasticity in adults.
The new muscles for treatment include additional muscles of the elbow and forearm, intrinsic hand muscles, and thumb muscles.
The label now includes the use of ultrasound as a muscle localization technique in adult spasticity.
Individuals with spasticity experience stiffness in the muscles of their upper or lower limbs and may have difficulty with voluntary control.
Price Action: ABBV shares were down 0.07% at $118.47 during the market session on the last check Thursday.

Posted In: Biotech News Health Care General BOTOX Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.